Overview

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Collaborator:
H. Lundbeck A/S
Treatments:
Duloxetine Hydrochloride
Vortioxetine